Drugs / BGB-23339
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05387668 | Feb → Oct 2022 | — | BeiGene | Withdrawn | No outcome recorded |
| Phase 1 | NCT05093270 | Nov 2021 → Sep 2022 | — | BeiGene | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-22 | BeOne Medicines | BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339 beonemedicines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-23339 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387668 ↗ |
| Route | Oral | “Administered orally as a tablet” NCT05093270 ↗ |